MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naïve Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA AnalysesJia Ruan, Peter Martin, David A. Bond et al.|Blood|2024Cited by 7
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphomaJia Ruan, Peter W. Martin, Sarah C. Rutherford et al.|Blood Advances|2025Cited by 3